Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

1 May 2012
by Working Group

Posted in Announcements, Events, TB News

Stop TB News – April 2012

stoptb-sheild-150

The latest news from the Stop TB Partnership as of April 2012.

11 Apr 2012

TB R&D Update: Strategies for Early and Late Stage Drug Development

9.cover

This week, we are highlighting two articles published online in the Journal of Infectious Diseases in March. The first article by Coxon, et al., looks at the benefits and limitations of the two main approaches to compound discovery for TB, target-based and phenotypic-based. The second article by Phillips, et al., would like TB clinical trialists to consider new strategies or designs for evaluating TB drug regimens which could alleviate a bottleneck as new drugs and consequently new potential drug combinations move into clinical testing. Additional links to TB R&D publications and news are included.

27 Mar 2012

TB R&D Update: 243rd American Chemistry Society Conference

acs-logo

The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29. There are several presentations on tuberculosis. Here are the abstracts of a few of the talks. The first item received news coverage and discusses two approved antibiotics that may prove effective in treating TB. Additional links to TB R&D News are included.

23 Mar 2012
by Working Group

Posted in Action, Announcements, Events, TB News

World TB Day! Overview of Events, News and Messages

wtd2012

Saturday, March 24, is officially World TB Day but there has been a stream of activities, publications, news and messages to let the world not forget about this major infectious disease killer that claims millions of lives each year. We present links and summaries of events, publications, messages, and news coverage leading up to World TB Day.

21 Mar 2012
by Working Group

Posted in Announcements, Events, TB Drug Development, TB News

World TB Day Coverage: New Combo TB Drug Trial Announced

img_0842

During the “Cure All: A briefing on the status of the most promising new TB drugs research” sponsored by the Critical Path to New TB Drug Regimens (CPTR) on Monday, March 19, Dr. Mel Spigelman, CEO & President, of TB Alliance announced the launch of the NC002 trial, a combination drug trial that establishes a new pathway to TB and multi-drug resistant TB treatment. The meeting also involved high-level officials from U.S. agencies that support TB research including Anthony Fauci (Director, NIAID/NIH), Janet Woodcock (Director, CDER/FDA), and Robert Clay (Deputy Assistant Administrator, Global Health Bureau/USAID).

9 Mar 2012

TB R&D Weekly Update: Results from Preventative Therapy Trial in SA Miners

Thibela-Combined-Logo

At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, results on the Thibela TB preventative therapy trial in South Africa gold miners was presented with mixed outcomes. Additional links to TB R&D news are included.

6 Mar 2012
by Working Group

Posted in Announcements, TB News

Death of TB Champion, Rep. Donald Payne

Payne

U.S. Representative Donald Payne from New Jersey died Tuesday, March 6. He will be remembered as a great champion of TB as well as malaria and HIV/AIDS.

TB R&D Weekly Update: Podcast Interview with Dr. Tawanda Gumbo

Tawanda_Gumbo.27720418_std

In this week’s interview, we discuss with Dr. Tawanda Gumbo his recently published paper that puts forth evidence that nonadherence may not be the prime reason for the emergence of drug resistance in TB, his research interests and background, the recent debate on the role of efflux pumps in drug tolerance and his research to optimize TB drugs. Additional links to TB R&D news are included.

23 Feb 2012

TB R&D Weekly Update: CSU Identifies Anti-TB Compound against Unique Target

ncb feb2012

This week’s article highlights research out of Colorado State University that identifies a potential anti-TB compound against a unique target– the inner membrane transporter MmpL3 of Mycobacterium tuberculosis–that inhibits an essential cell function of the mycobacteria. Additional links to TB R&D News are included.

14 Feb 2012
by Tamzin_Furtado

Posted in Action, Announcements, Events, TB News

Innovative Professional Development Resource for Clinical Researchers and More

globalhealthtrials

We would like to share an exciting development in the field of global health, which has been launched in the last six months – an innovative professional membership scheme for tracking the continued professional development of clinical research staff across all types of trials and all regions.